Since the first therapeutic monoclonal antibody was approved by the US Food and Drug Administration (FDA) in 1986, the field of antibody therapy development has increased, yet it continues to face many challenges. The scarcity of antigen-specific B cells is one of the hurdles scientists face early-on when developing a monoclonal antibody to treat cancer, autoimmune disease or infection. In this webinar, learn about enhancing antibody discovery with novel strategies — such as the one developed by Single Cell Technology — that enable the accelerated generation of neutralizing monoclonal antibodies from influenza-vaccinated individuals.
Join this webinar to learn about the benefits of this approach for:
- Expansion and activation of memory B cells
- Isolation of antigen-specific memory B cells from vaccinated individuals with faster, gentler and safer microchip-based cell sorting
- Capture and sequencing of antigen-specific antibodies using a novel platform for antibody discovery that uses next-gen sequencing technology
- Creation, expression and cross-reactivity testing of recombinant antibodies
Chun-Nan Chen, PhD, Chief Executive Officer, Single Cell Technology
Dr. Chun-Nan Chen is the CEO at Single Cell Technology, which he founded in 2008 with his two partners. Dr. Chen led a team as part of an international consortium contributing to the Human Genome Project. Since then, he has a long history of research and applications in molecular biology and sequencing and is dedicated to innovating new strategies incorporating the latest trends in NGS. Dr. Chen is a registered United States Patent Agent.
Allison Schulkins, Chief Operating Officer, Single Cell Technology
Allison Schulkins has spent 10 years at Single Cell leading efforts to improve and validate processes in cell isolation, antibody screening, and amplification techniques for Next Generation Sequencing. Allison uses her expertise across Single Cell’s converging fields to manage laboratory operations, customize discovery campaigns for new challenges, and set up strategic alliances. Allison has a B.S. in Biochemistry from University of California, Santa Barbara and an M.S. in Chemical Engineering from San Jose State University.
Crystal Montoya, Senior Marketing Product Manager, Miltenyi Biotec
Bio coming soon.
Who Should Attend?
This webinar will be ideal for academic and pharmaceutical researchers who are interested in isolating, identifying and sequencing antigen-specific B cells and monoclonal antibodies.
What You Will Learn
Attendees will gain insights into:
- The challenges of developing a novel monoclonal antibody
- How a unique cell sorter using high-speed multiparameter flow sorting isolates rare and functional cells in a sterile, closed environment
- A novel platform that fast-tracks antibody discovery by providing comprehensive characterization of a wide selection of high affinity monoclonal antibodies
For over 30 years, Miltenyi Biotec has been a leader in the development of products that empower the advancement of biomedical research and enable cell and gene therapy. We provide innovative tools to help with your sample preparation, cell isolation, cell culture, and cell analysis needs. Our solutions are designed to support everything from basic research to translational research and clinical application for immunology, stem cell biology, neuroscience, and cancer.